BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $14.04 Million Stake in AtriCure, Inc. (NASDAQ:ATRC)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 31.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 500,649 shares of the medical device company's stock after buying an additional 119,929 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 1.03% of AtriCure worth $14,038,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. ProShare Advisors LLC lifted its position in AtriCure by 8.5% during the first quarter. ProShare Advisors LLC now owns 8,371 shares of the medical device company's stock valued at $255,000 after buying an additional 659 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of AtriCure by 34.3% during the first quarter. State Board of Administration of Florida Retirement System now owns 17,859 shares of the medical device company's stock worth $543,000 after purchasing an additional 4,560 shares in the last quarter. Bessemer Group Inc. lifted its position in shares of AtriCure by 29.7% during the first quarter. Bessemer Group Inc. now owns 35,500 shares of the medical device company's stock worth $1,080,000 after purchasing an additional 8,120 shares in the last quarter. Mount Yale Investment Advisors LLC bought a new stake in shares of AtriCure in the first quarter worth $224,000. Finally, Bayesian Capital Management LP bought a new stake in AtriCure during the first quarter valued at $344,000. 99.11% of the stock is owned by institutional investors and hedge funds.

AtriCure Price Performance

NASDAQ ATRC traded up $0.05 on Friday, reaching $35.74. The company's stock had a trading volume of 459,821 shares, compared to its average volume of 741,642. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $42.99. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62. The stock has a market cap of $1.74 billion, a PE ratio of -43.05 and a beta of 1.41. The firm's 50 day moving average is $30.93 and its two-hundred day moving average is $25.90.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. The company had revenue of $115.91 million during the quarter, compared to the consensus estimate of $112.23 million. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. AtriCure's revenue was up 17.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.20) EPS. As a group, sell-side analysts predict that AtriCure, Inc. will post -0.72 EPS for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on ATRC shares. JPMorgan Chase & Co. boosted their target price on shares of AtriCure from $30.00 to $40.00 and gave the company an "overweight" rating in a research note on Wednesday, October 30th. Piper Sandler lowered their target price on shares of AtriCure from $65.00 to $40.00 and set an "overweight" rating for the company in a research note on Wednesday, July 31st. Oppenheimer upped their price target on shares of AtriCure from $32.00 to $36.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Stifel Nicolaus lowered their price target on shares of AtriCure from $30.00 to $26.00 and set a "buy" rating for the company in a research report on Wednesday, July 31st. Finally, Needham & Company LLC upped their price target on shares of AtriCure from $34.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $43.11.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.